Q2 2026 Results Date Confirmed - 28 July 2026

Summary by AI BETAClose X

GSK plc has announced that its Q2 2026 results will be published on Tuesday, 28 July 2026, and will include an update on portfolio growth opportunities. The company also provided indicative dates for its Q3 2026 results on Wednesday, 28 October 2026, and Q4 2026 results on Wednesday, 3 February 2027, along with associated ex-dividend, record, and payment dates for ordinary shares and American Depositary Shares for the remainder of the financial year.

Disclaimer*

GSK PLC
22 May 2026
 

GSK plc

 

GSK confirms that the Company's Q2 2026 results are due to be published via the London Stock Exchange on Tuesday 28 July 2026. GSK will also provide an update on portfolio growth opportunities.

 

The results announcement dates and respective record and dividend dates for the remainder of the financial year are set out below:

 

Results

Announcement date

Ordinary Shares Ex-dividend date

American Depositary Shares Ex-dividend date

Record date

Last date for DRIP elections

Payable

Q2 2026

Tuesday 28 July 2026

Thursday 13 August 2026

 

Friday 14 August 2026

 

Friday 14 August 2026

Thursday 17 September 2026

Thursday 8 October 2026

Q3 2026

 

Wednesday 28 October 2026

 

Thursday 12 November 2026

Friday 13 November 2026

Friday 13 November 2026

Monday 14 December 2026

Thursday 7 January 2027

Q4 2026

 

Wednesday 3 February 2027

 

Thursday 18 February 2027

Friday 19 February 2027

Friday 19 February 2027

Tuesday 16 March 2027

Thursday 8 April 2027

 

These dates are indicative and may be subject to change.  

 

 

V A Whyte

Company Secretary

 

22 May 2026

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

GSK (GSK)
UK 100

Latest directors dealings